Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion

Mirati develops commercial-stage oncology therapies, and through the deal, Bristol Myers Squibb will add lung-cancer medicine Krazati, among others, to its portfolio.